Table 2 |.
Summary of the first patients treated on the NCI adult autologous anti-CD19 CAR trial33
| Patient* | Age (years) | Malignancy | Number of unique prior therapies | Number of CAR-expressing T cells infused per kg | Response (duration in months after T-cell infusion) |
|---|---|---|---|---|---|
| 1a‡ | 47 | Follicular lymphoma | 4 | 0.3 × 107 | PR (7) |
| 1b‡ | 48 | Follicular lymphoma | 5 | 1.3 × 107 | PR (33) |
| 2 | 48 | Follicular lymphoma | 5 | 0.3 × 107 | NE |
| 3 | 61 | Chronic lymphocytic leukaemia | 3 | 1.1 × 107 | CR (24) |
| 4 | 55 | Splenic, marginal zone lymphoma | 3 | 1.1 × 107 | PR (12) |
| 5 | 54 | Chronic lymphocytic leukaemia | 4 | 0.3 × 107 | SD (6) |
| 6 | 57 | Chronic lymphocytic leukaemia | 7 | 1.7 × 107 | PR (7) |
| 7 | 61 | Chronic lymphocytic leukaemia | 4 | 2.8 × 107 | CR (21+) |
| 8 | 63 | Follicular lymphoma | 7 | 3.0 × 107 | PR (11)§ |
*
All eight patients were male.
‡
Patient 1 was treated twice.
§
Not evaluable for malignancy response beyond 11 months because the patient developed laryngeal carcinoma. Abbreviations: CAR, chimeric antigen receptor; CR, complete remission; NE, not evaluable for malignancy response because the patient died with influenza pneumonia; PR, partial remission; SD, stable disease.